Solvemed Group
Matt Heller has a diverse and extensive work experience in various roles and industries. In 2014, they started as a Research Scientist in Psychiatric Neuroscience at the New York State Psychiatric Institute and later moved to a similar role at Columbia University Irving Medical Center. In 2017, they joined NewYork-Presbyterian Hospital as a Clinical R&D and Implementation Manager in Orthopaedic Surgery. In 2018, they became an Engineering Graduate Student and Graduate Student Instructor at Brown University School of Engineering.
In 2019, Matt took on multiple roles. Matt served as Chief Innovation Officer at Alex Therapeutics, a venture-backed company that focused on bridging the gap between innovation, healthcare, and business strategies. Matt also worked as the Global Head of Business Development and Expansion at Alex Therapeutics for a brief period. Additionally, they were appointed Head of R&D Partnerships and Software Medical Device Research Scientist at both Karolinska Institutet and the Public Health Foundation of India (PHFI).
In 2020, Matt became the Head of International Business Development at PharmaLogics Recruiting. Then in 2021, they joined Capsule as the Expansion Business Development, Enterprise Lead. At Capsule, they established a pioneering 94 NPS retail pharmacy tech unicorn-health system ACO partnership, which enhanced healthcare services for approximately 3 million covered lives across underserved communities in the United States.
Currently, Matt Heller holds the position of Global Head of Partnerships at Solvemed Group, a Marcin Zukowski and Thiel Foundation-backed neuro-technology firm. Matt is leading the development of first-in-class digital neuro-ocular biomarker diagnostic technology using AI as software medical devices to transform care delivery and drug development. Solvemed Group has operations in Silicon Valley, Boston, London, and Poland.
Overall, Matt Heller's work experience demonstrates their expertise in research, innovation, business development, and partnerships within the healthcare and technology sectors.
Matt Heller has studied Business Engineering, Technology Innovation Economic and Management Theory, and Biotechnology at Brown University. Matt has also pursued Clinical Neuroscience at Columbia University and Neuroscience and Buddhism at Boston University. However, specific start and end years for their education at these institutions are not provided.
This person is not in any offices
Solvemed Group
At Solvemed Group, we believe in challenging the status quo of neurological care. Our founders experienced first-hand the grave consequences of poor diagnostic standards in neurodegenerative diseases. With the primary focus in Parkinson’s disease, we leverage our proprietary machine learning technology to develop novel diagnostic-predictive digitalbiomarkers to enable first-in-class, accurate, early and cost-effective diagnostic and monitoring tools. In everything we do, we put the needs of patients and healthcare professionals first. We also happen to revolutionise drug discovery as our biomarkers enable disease-modifying drugs.We respond to the unmet needs of neurological patients by providing reliable, accurate, early diagnostics and monitoring tools for better quality care and treatment outcomes. Our work has the potential to improve healthcare systems by optimising relevant care pathways and reducing the financial burden imposed by inadequate diagnostics. Through our proprietary medical data repositories, we work with our biopharmaceutical industry partners driving clinical trial efficiency and making first-in-class disease-modifying drugs possible.Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as Oxford University, University College London, Harvard Medical School and Duke University, among other.